Astrocytic brain tumors


Key articles

Buckner JC, Shaw EG, Pugh SL, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med. 2016 Apr 7;374(14):1344-55.Full text  Abstract

National Institute for Health and Care Excellence. Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma. Jun 2007 [internet publication].Full text

Ryken TC, Frankel B, Julien T, et al. Surgical management of newly diagnosed glioblastoma in adults: role of cytoreductive surgery. J Neurooncol. 2008 Sep;89(3):271-86. Abstract

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: central nervous system cancers. 2019 [internet publication].Full text

Reference articles

1. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016 Jun;131(6):803-20.Full text  Abstract

2. Burkhard C, Di Patre PL, Schuler D, et al. A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma. J Neurosurg. 2003 Jun;98(6):1170-4. Abstract

3. Arita K, Kurisu K, Tominaga A, et al. Intrasellar pleomorphic xanthoastrocytoma: case report. Neurosurgery. 2002 Oct;51(4):1079-82. Abstract

4. Epstein F, Farmer JP. Brainstem glioma growth patterns. J Neurosurg. 1993 Mar;78(3):408-12. Abstract

5. Reigel DH, Scarff TB, Woodford JE. Biopsy of pediatric brain stem tumors. Childs Brain. 1979;5(3):329-40. Abstract

6. Ostrom QT, Gittleman H, Truitt G, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015. Neuro Oncol. 2018 Oct 1;20(suppl 4):iv1-iv86.Full text  Abstract

7. DiMario FJ Jr. Brain abnormalities in tuberous sclerosis complex. J Child Neurol. 2004 Sep;19(9):650-7. Abstract

8. Kitange GJ, Templeton KL, Jenkins RB. Recent advances in molecular genetics of primary gliomas. Curr Opin Oncol. 2003 May;15(3):197-203. Abstract

9. Fisher JL, Schwartzbaum JA, Wrensch M, et al. Evaluation of epidemiologic evidence for primary adult brain tumor risk factors using evidence-based medicine. Prog Neurol Surg. 2006;19:54-79. Abstract

10. Rothman KJ. Health effects of mobile telephones. Epidemiology. 2009 Sep;20(5):653-5. Abstract

11. Hardell L, Carlberg M, Hansson Mild K. Use of mobile phones and cordless phones is associated with increased risk for glioma and acoustic neuroma. Pathophysiology. 2013 Apr;20(2):85-110. Abstract

12. Corle C, Makale M, Kesari S. Cell phones and glioma risk: a review of the evidence. J Neurooncol. 2012 Jan;106(1):1-13. Abstract

13. Kan P, Simonsen SE, Lyon JL, et al. Cellular phone use and brain tumor: a meta-analysis. J Neurooncol. 2008 Jan;86(1):71-8. Abstract

14. Myung SK, Ju W, McDonnell DD, et al. Mobile phone use and risk of tumors: a meta-analysis. J Clin Oncol. 2009 Nov 20;27(33):5565-72.Full text  Abstract

15. Ahlbom A, Feychting M, Green A, et al. Epidemiologic evidence on mobile phones and tumor risk: a review. Epidemiology. 2009 Sep;20(5):639-52. Abstract

16. Samkange-Zeeb F, Schlehofer B, Schüz J, et al. Occupation and risk of glioma, meningioma and acoustic neuroma: results from a German case-control study (interphone study group, Germany). Cancer Epidemiol. 2010 Feb;34(1):55-61. Abstract

17. Wrensch M, Minn Y, Chew T, et al. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol. 2002 Oct;4(4):278-99.Full text  Abstract

18. Blatt J, Jaffe R, Deutsch M, et al. Neurofibromatosis and childhood tumors. Cancer. 1986 Mar 15;57(6):1225-9. Abstract

19. Singhal S, Birch JM, Kerr B, et al. Neurofibromatosis type I and sporadic optic gliomas. Arch Dis Child. 2002 Jul;87(1):65-70. Abstract

20. Tao ML, Barnes PD, Billett AL, et al. Childhood optic chiasm gliomas: radiographic response following radiotherapy and long-term clinical outcome. Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):579-87. Abstract

21. Listernick R, Charrow J, Greenwald MJ, et al. Natural history of optic nerve pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr. 1994 Jul;125(1):63-6. Abstract

22. Braffman BH, Bilaniuk LT, Naidich TP, et al. MR imaging of tuberous sclerosis: pathogenesis of this phakomatosis, use of gadopentetate dimeglumine, and literature review. Radiology. 1992 Apr;183(1):227-38. Abstract

23. Shepherd CW, Scheithauer BW, Gomez MR, et al. Subependymal giant cell astrocytoma: a clinical, pathological, and cytometric study. Neurosurgery. 1991 Jun;28(6):864-8. Abstract

24. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990 Nov 30;250(4985):1233-8. Abstract

25. Hamilton SR, Liu B, Parsons RE, et al. The molecular basis of Turcot's syndrome. N Engl J Med. 1995 Mar 30;332(13):839-47.Full text  Abstract

26. Paulino AC, Mai WY, Chintagumpala M, et al. Radiation-induced malignant gliomas: is there a role for reirradiation? Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1381-7. Abstract

27. Gurney JG, Kadan-Lottick N. Brain and other central nervous system tumors: rates, trends and epidemiology. Curr Opin Oncol. 2001 May;13(3):160-6. Abstract

28. Vecht CJ, Wagner GL, Wilms EB. Treating seizures in patients with brain tumors: drug interactions between antiepileptic and chemotherapeutic agents. Semin Oncol. 2003 Dec;30(6 suppl 19):49-52. Abstract

29. Snyder H, Robinson K, Shah D, et al. Signs and symptoms of patients with brain tumors presenting to the emergency department. J Emerg Med. 1993 May-Jun;11(3):253-8. Abstract

30. DeAngelis LM. Brain tumors. N Engl J Med. 2001 Jan 11;344(2):114-23. Abstract

31. Whittle IR, Pringle AM, Taylor R. Effects of resective surgery for left-sided intracranial tumors on language function: a prospective study. Lancet. 1998 Apr 4;351(9108):1014-8. Abstract

32. Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery. 2007 Nov;61(5):935-48. Abstract

33. Kickingereder P, Andronesi OC. Radiomics, metabolic, and molecular MRI for brain tumors. Semin Neurol. 2018 Feb;38(1):32-40. Abstract

34. Grimstad IA, Hirschberg H, Rootwelt K. 99m Tc-hexamethyl propyleneamine oxime leukocyte scintigraphy and C-reactive protein levels in the differential diagnosis of brain abscess. J Neurosurg. 1992 Nov;77(5):732-6. Abstract

35. Lee YY, Van Tassel P, Bruner JM, et al. Juvenile pilocytic astrocytomas: CT and MR characteristics. AJR Am J Roentgenol. 1989 Jun;152(6):1263-70.Full text  Abstract

36. Stupp R, Brada M, van den Bent MJ, et al. High-grade glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014 Sep;25(suppl 3):iii93-101.Full text  Abstract

37. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsivant prophylaxis in patients with newly diagnosed brain tumors. Report of the quality standard subcommittee of the American Academy of Neurology. Neurology. 2000 May 23;54(10):1886-93. Abstract

38. Galicich JH, French LA. Use of dexamethasone in the treatment of cerebral edema from brain tumors and brain surgery. AM Pract Dig Treat. 1961 Mar;12:169-74. Abstract

39. Sasongko TH, Ismail NF, Zabidi-Hussin Z. Rapamycin and rapalogs for tuberous sclerosis complex. Cochrane Database Syst Rev. 2016 Jul 13;7:CD011272.Full text  Abstract

40. Franz DN, Belousova E, Sparagana S, et al. Long-term use of everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 study. PLoS One. 2016 Jun 28;11(6):e0158476.Full text  Abstract

41. Ater JL, Zhou T, Holmes E, et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. J Clin Oncol. 2012 Jul 20;30(21):2641-7.Full text  Abstract

42. Packer RJ, Lange B, Ater J, et al. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol. 1993 May;11(5):850-6. Abstract

43. Prados MD, Edwards MS, Rabbitt J, et al. Treatment of pediatric low-grade gliomas with nitrosurea-based multiagent chemotherapy regimen. J Neurooncol. 1997 May;32(3):235-41. Abstract

44. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008 Apr;62(4):753-64. Abstract

45. Tihan T, Fisher PG, Kepner JL, et al. Pediatric astrocytomas with monomorphous pilomyxoid features and a less favorable outcome. J Neuropathol Exp Neurol. 1999 Oct;58(10):1061-8. Abstract

46. Buckner JC, Shaw EG, Pugh SL, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med. 2016 Apr 7;374(14):1344-55.Full text  Abstract

47. Stummer W, van den Bent MJ, Westphal M. Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion. Acta Neurochir (Wien). 2011 Jun;153(6):1211-8. Abstract

48. Wick W, Platten M, Meisner C, et al.Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012 Jul;13(7):707-15. Abstract

49. Malmström A, Grønberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012 Sep;13(9):916-26. Abstract

50. Westphal M, Ram Z, Riddle V, et al. Gliadel wafer in initial surgery for malignant gliomas: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien). 2006 Mar;148(3):269-75. Abstract

51. National Institute for Health and Care Excellence. Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma. Jun 2007 [internet publication].Full text

52. Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. Cochrane Database Syst Rev. 2011;(3):CD007294.Full text  Abstract

53. Herrlinger U, Tzaridis T, Mack F, et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet. 2019 Feb 16;393(10172):678-88. Abstract

54. Buie LW, Valgus J. Bevacizumab: a treatment option for recurrent glioblastoma multiforme. Ann Pharmacother. 2008 Oct;42(10):1486-90. Abstract

55. Ameratunga M, Pavlakis N, Wheeler H, et al. Anti-angiogenic therapy for high-grade glioma. Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218.Full text  Abstract

56. Fisher BJ, Leighton CC, Vujovic O, et al. Results of a policy of surveillance alone after surgical management of pediatric low grade gliomas. Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):704-10. Abstract

57. Hadjipanayis CG, Kondziolka D, Gardner P, et al. Stereotactic surgery for pilocytic astrocytomas when multimodal therapy is necessary. J Neurosurg. 2002 Jul;97(1):56-64. Abstract

58. Pierce SM, Barnes PD, Loeffler JS, et al. Definitive radiation therapy in the management of symptomatic patients with optic nerve glioma. Survival and long-term effects. Cancer. 1990 Jan 1;65(1):45-52. Abstract

59. Turgut M, Akalan N, Ozgen T, et al. Subependymal giant cell astrocytoma associated with tuberous sclerosis: diagnosis and surgical caracteristics of five cases with unusual features. Clin Neurol Neurosurg. 1996 Aug;98(3):217-21. Abstract

60. Fouladi M, Jenkins J, Burger P, et al. Pleomorphic xanthoastrocytoma: favorable outcome after complete surgical resection. Neuro Oncol. 2001 Jul;3(3):184-92. Abstract

61. Karim AB, Afra D, Cornu P, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: EORT-22845 with the Medical Research Council Study BR04: an interim analysis. Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):316-24. Abstract

62. Shaw EG, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol. 2002 May 1;20(9):2267-76. Abstract

63. Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol. 2012 Sep 1;30(25):3065-70. Abstract

64. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987-96. Abstract

65. Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. Cochrane Database Syst Rev. 2011 Mar 16;(3):CD007294.Full text  Abstract

66. Ryken TC, Frankel B, Julien T, et al. Surgical management of newly diagnosed glioblastoma in adults: role of cytoreductive surgery. J Neurooncol. 2008 Sep;89(3):271-86. Abstract

67. Buatti J, Ryken TC, Smith MC, et al. Radiation therapy of pathologically confirmed newly diagnosed glioblastoma in adults. J Neurooncol. 2008 Sep;89(3):313-37. Abstract

68. Olson JJ, Ryken T. Guidelines for the treatment of newly diagnosed glioblastoma: introduction. J Neurooncol. 2008 Sep;89(3):255-8. Abstract

69. Freeman CR, Farmer J-P. Pediatric brain stem gliomas: a review. Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):265-71. Abstract

70. Lashford LS, Thiesse P, Jouvet A, et al. Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol. 2002 Dec 15;20(24):4684-91. Abstract

71. Bowers DC, Krause TP, Aronson LJ, et al. Second surgery for recurrent pilocytic astrocytoma in children. Pediatr Neurosurg. 2001 May;34(5):229-34. Abstract

72. Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol. 2003 Dec;14(12):1722-6.Full text  Abstract

73. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet. 1995 Apr 22;345(8956):1008-12. Abstract

74. Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience. Curr Med Res Opin. 2008 Nov;24(11):3239-57. Abstract

75. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol. 1999 Sep;17(9):2762-71. Abstract

76. Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol. 2010 Oct 20;28(30):4601-8.Full text  Abstract

77. National Institute for Health and Care Excellence. Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal). Jun 2008 [internet publication].Full text

78. ANG1005 in patients with recurrent high-grade glioma. Sep 2017 [internet publication].Full text

79. Stage 1: marizomib + bevacizumab in WHO Gr IV GBM; Stage 2: marizomib alone. NCT02330562. Jul 2019 [internet publication].Full text

80. Omuro A, Vlahovic G, Lim M, et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol. 2018 Apr 9;20(5):674-86.Full text  Abstract

81. Cloughesy TF, Mochizuki AY, Orpilla JR, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019 Mar;25(3):477-86.Full text  Abstract

82. Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat Med. 2019 Mar;25(3):470-6. Abstract

83. Tivnan A, Heilinger T, Lavelle EC, et al. Advances in immunotherapy for the treatment of glioblastoma. J Neurooncol. 2017 Jan;131(1):1-9.Full text  Abstract

84. Weller M, Butowski N, Tran DD, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1373-85. Abstract

85. Desjardins A, Gromeier M, Herndon JE 2nd, et al. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med. 2018 Jul 12;379(2):150-61.Full text  Abstract

86. Lang FF, Conrad C, Gomez-Manzano C, et al. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol. 2018 May 10;36(14):1419-27.Full text  Abstract

87. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012 Sep;48(14):2192-202. Abstract

88. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017 Dec 19;318(23):2306-16.Full text  Abstract

89. Chen S, Visintini S, eds. Extended dosing (12 cycles) of adjuvant temozolomide in adults with newly diagnosed high grade gliomas: a review of clinical effectiveness, cost-effectiveness, and guidelines. Feb 2018 [internet publication].Full text  Abstract

90. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: central nervous system cancers. 2019 [internet publication].Full text

91. Pace A, Dirven L, Koekkoek JAF, et al. European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. Lancet Oncol. 2017 Jun;18(6):e330-40. Abstract

92. Giannini C, Scheithauer BW, Burger PC, et al. Pleomorphic xanthoastrocytoma: what do we really know about it? Cancer. 1999 May 1;85(9):2033-45. Abstract

93. Hamilton MG, Hull RD, Pineo GH. Venous thromboembolism in neurosurgery and neurology patients: a review. Neurosurgery. 1994 Feb;34(2):280-96. Abstract

Use of this content is subject to our disclaimer